Table 2.
HIPEC and EPIC regimens
| Primary | N | |
|---|---|---|
| HIPEC | ||
| DOX (15 mg/m2), CPL (50 mg/m2) | G, M, O, A | 29 |
| CPL (75 mg/m2) | M | 1 |
| CPL (75 mg/m2), MMC (30 mg/m2) | G, M | 11 |
| MMC (15 mg/m2) | CR, A | 2 |
| DOX (15 mg/m2), MMC (15 mg/m2) | CR, A | 32 |
| OXA (460 mg/m2), LV* (20 mg/m2), 5-FU* (400 mg/m2) | CR, A, I | 39 |
| OXA (460 mg/m2) | CR, A, G, I | 5 |
| OXA (460 mg/m2), MMC (15 mg/m2) | G | 2 |
| HIPEC + EPIC | ||
| DOX (15 mg/m2), CPL (50 mg/m2) + TAX (80 mg/m2) | O, M | 10 |
| DOX (15 mg/m2), MMC (15 mg/m2) + 5-FU (650 mg/m2) | CR, A | 25 |
| OXA (460 mg/m2), LV* (20 mg/m2), 5-FU* (400 mg/m2) + 5-FU (650 mg/m2) | CR | 1 |
HIPEC hyperthermic intraperitoneal chemotherapy, EPIC early postoperative intraperitoneal chemotherapy, G gastric cancer, M mesothelioma, O ovarian cancer, A appendiceal neoplasms, CR colorectal cancer, I intestinal cancer, CPL cisplatin, MMC mitomycin C, DOX doxorubicin, TAX taxol, 5-FU 5-fluorouracil, OXA oxaliplatin, LV leucovorin
*i.v. chemotherapy (bidirectional)